Mabapi le mofetše / kalafo / liteko tsa bongaka / lefu / intraocular-melanoma / kalafo
Liteko tsa Kalafo ea Kalafo bakeng sa Melanoma ea Intraocular
Liteko tsa bongaka ke lithuto tsa lipatlisiso tse amang batho. Liteko tsa bongaka lethathamong lena ke tsa kalafo ea melanoma ea intraocular. Liteko tsohle tse lenaneng li tšehelitsoe ke NCI.
Tlhahisoleseling ea mantlha ea NCI mabapi le liteko tsa bongaka e hlalosa mefuta le mekhahlelo ea liteko le hore na li etsoa joang. Liteko tsa bongaka li sheba mekhoa e mecha ea ho thibela, ho lemoha kapa ho phekola mafu. U kanna ua batla ho nahana ka ho nka karolo tekong ea bongaka. Bua le ngaka ea hau bakeng sa thuso ho etsa qeto ea hore na e nepahetse ho uena.
Liteko 1-25 ho 25
Ts'ireletseho le Ts'ebetso ea IMCgp100 Khahlano le Khetho ea Mofuputsi ho Advanced Uveal Melanoma
Ho lekola pholoho e akaretsang ea bakuli ba baholo ba HLA-A * 0201 ba nang le UM ea pele e neng e sa alafshoa ba amohelang IMCgp100 ha ba bapisoa le Khetho ea Mofuputsi oa dacarbazine, ipilimumab, kapa pembrolizumab.
Sebaka: libaka tse 19
A Study of XmAb®22841 Monotherapy & in Combination w / Pembrolizumab in Subjects w / Selected Advanced Solid Tumors
Ena ke Phase 1, tekanyetso e mengata, thuto ea ho nyoloha ha litekanyetso le thuto ea katoloso e etselitsoeng ho hlalosa tekanyetso e mamelletsoeng haholo le / kapa tekanyetso e khothalelitsoeng ea monmotherapy ea XmAb22841 mme e kopane le pembrolizumab; ho lekola polokeho, mamello, pharmacokinetics, immunogenicity, le anti-tumor ts'ebetso ea XmAb22841 monotherapy le hammoho le pembrolizumab lithutong tse nang le lihlahala tse tiileng tse tsoetseng pele.
Sebaka: libaka tse 10
Boithuto ba RP1 Monotherapy le RP1 ka Kopanyo le Nivolumab
RPL-001-16 ke Phase 1/2, label e bulehileng, keketseho ea tekanyetso le thuto ea bongaka ea katoloso ea RP1 feela mme e kopane le nivolumab lithutong tsa batho ba baholo tse nang le lihlahala tse tiileng tse tsoetseng pele le / kapa tse hanyetsanang, ho fumana tekanyetso e mamellehang haholo (MTD) le tekanyetso e khothalelitsoeng ea Phase 2 (RP2D), hammoho le ho lekola katleho ea pele.
Sebaka: libaka tse 6
Ithute ka Lihlooho le Melanoma e Nyane ea Mantlha ea Choroidal
Morero oa mantlha ke ho lekola polokeho, boits'oaro ba mmele le ts'ebetso ea e 'ngoe ea litekanyetso tse tharo tsa tekanyetso le ho pheta mefuta ea litekanyetso tsa AU-011 e sebelisitsoeng ke Leseli le kopo e le' ngoe kapa tse peli tsa laser bakeng sa kalafo ea lithuto ka melanoma ea mantlha ea choroidal.
Sebaka: libaka tse 4
Phuputso ea IDE196 ho bakuli ba nang le lihlahala tse tiileng tse bolokang liphetoho tsa GNAQ / 11 kapa PRKC Fusions
Ena ke Phase 1/2, setsi se nang le li-multi-label, open-label basket e etselitsoeng ho lekola ts'ireletso le anti-tumor ts'ebetso ea IDE196 ho bakuli ba nang le lihlahala tse tiileng tse bolokang liphetoho tsa GNAQ kapa GNA11 (GNAQ / 11) kapa liphetoho tsa PRKC, ho kenyeletsoa metastatic uveal melanoma (MUM), melanoma e sa khaotseng, kankere e khanyang, le lihlahala tse ling tse tiileng. Mokhahlelo oa 1 (keketseho ea lethal dose) o tla lekola polokeho, mamello le litlhare tsa meriana tsa IDE196 ka sekema se tloaelehileng sa keketseho ea tekanyetso le ho fumana tekanyetso ea Phase 2 e khothalletsoang. Ts'ebetso ea polokeho le anti-hlahala e tla hlahlojoa Karolong ea 2 (katoloso ea tekanyetso) ea thuto.
Sebaka: libaka tse 4
Selumetinib Sulfate ho Phekola Bakuli ba nang le Uveal Melanoma kapa GNAQ / GNA11 Melanoma e fetotsoeng e nang le metastatic kapa e ke keng ea tlosoa ke ho buoa
Karolo ena ea liteko tsa Ib e hlahloba litla-morao le lethal dose ea selumetinib sulfate ho phekola bakuli ba nang le melanoma ea uveal kapa GNAQ / GNA11 e fetotseng melanoma e hasaneng ho tloha sebakeng sa mantlha ho ea libakeng tse ling 'meleng kapa e ke keng ea tlosoa ka ho buuoa. Selumetinib sulfate e ka emisa kholo ea lisele tsa hlahala ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea lisele.
Sebaka: libaka tse 3
Virus e fetotsoeng VSV-IFNbetaTYRP1 ho Phekola bakuli ba nang le Melanoma ea Stage III-IV
Karolo ena ea liteko tsa karolo ena ea pele e hlahloba litla-morao le lethal dose ea vaerase e fetotsoeng e bitsoang VSV-IFNbetaTYRP1 ho phekola bakuli ba melanoma ea III-IV. Kokoana-hloko ea vesicular stomatitis (VSV) e fetotsoe hore e kenye liphatsa tsa lefutso tse ling tse peli: interferon beta ea motho (hIFNbeta), e ka sireletsang lisele tse tloaelehileng tse phetseng hantle hore li se ke tsa tšoaetsoa ke vaerase, le TYRP1, e hlahisoang haholo ke melanocyte (sele e khethehileng ea letlalo e e hlahisa letlalo le sireletsang letlalo le fifatsang 'mala oa melanin) le lisele tsa hlahala ea melanoma, mme e ka baka karabelo e matla ea boits'ireletso ba mmele ho bolaea lisele tsa hlahala ea melanoma.
Sebaka: libaka tse 2
Boithuto ba PLX2853 ho Malignancies a Tsoetseng Pele.
Morero oa phuputso ena ke ho lekola polokeho, pharmacokinetics, pharmacodynamics le katleho ea pele ea moriana oa lipatlisiso PLX2853 lithutong tse nang le malignancies a tsoetseng pele.
Sebaka: libaka tse 2
Yttrium90, Ipilimumab, & Nivolumab bakeng sa Uveal Melanoma Le Metastases ea Sebete
Litlaleho ho fihlela joale li bonts'a katleho e fokolang ea immunotherapy bakeng sa uveal melanoma. Bopaki ba morao-rao ba liteko le tsa bongaka bo bontša tšebelisano lipakeng tsa kalafo ea radiation le immunotherapy. Bafuputsi ba tla hlahloba ts'ebelisano ena ka ho etsa lipatlisiso tsa bakuli ba 26 ba nang le uveal melanoma le metastases ea hepatic ba tla amohela SirSpheres Yttrium-90 mahlaseli a ka hare a hepatic a lateloang ke immunotherapy ka kopanyo ea ipilimumab le nivolumab.
Sebaka: libaka tse 2
Pegargiminase, Nivolumab le Ipilimumab ho Phekola Bakuli ba nang le Melanoma e Phahameng kapa e sa Khetholloeng ea Melanoma.
Karolo ena ea liteko tsa karolo ea pele e hlahloba litla-morao tsa pegargiminase, nivolumab le ipilimumab ho phekola bakuli ba nang le melanoma ea uveal e hasaneng libakeng tse ling 'meleng (e tsoetseng pele) kapa e ke keng ea tlosoa ka ho buuoa (e ke keng ea qojoa). Pegargiminase e ka emisa kholo ea lisele tsa hlahala ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea lisele. Immunotherapy e nang le li-antibodies tsa monoclonal, joalo ka nivolumab le ipilimumab, e ka thusa sesole sa 'mele ho hlasela mofets'e, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana. Ho fana ka pegargiminase, nivolumab le ipilimumab ho ka ba betere ha ho bapisoa le immunotherapy feela.
Sebaka: Memorial Sloan Kettering Cancer Center, New York, New York
Phekolo ea mahlaseli a 'mele ea Stereotactic Therapy le Aflibercept ho phekola bakuli ba nang le Uveal Melanoma
Teko ena ea mohato oa II e ithuta hore na kalafo ea mahlaseli a kotsi a 'mele e sebetsa joang ho phekoleng bakuli ba nang le melanoma. Phekolo ea radiation ea 'mele ea stereotactic e sebelisa lisebelisoa tse ikhethang ho beha mokuli le ho tsamaisa mahlaseli ho lihlahala ka nepo e phahameng. Mokhoa ona o ka bolaea lisele tsa hlahala ka tekanyetso e fokolang ka nako e khuts'oane mme ea baka tšenyo e nyane ho lisele tse tloaelehileng. Aflibercept e ka emisa kholo ea lisele tsa hlahala ka ho thibela li-enzyme tse ling tse hlokahalang bakeng sa kholo ea lisele. Ho fana ka kalafo ea radiation ea 'mele e lateloang ke aflibercept ho ka sebetsa hantle ho phekola bakuli ba nang le melanoma ea uveal.
Sebaka: Sepetlele sa Thomas Jefferson University, Philadelphia, Pennsylvania
Boithuto ba polokeho le mamello ea INCAGN02390 ho Select Advanced Malignancies
Morero oa phuputso ena ke ho netefatsa polokeho, mamello le katleho ea pele ea INCAGN02390 ho bankakarolo ba nang le likotsi tse tsoetseng pele.
Sebaka: Setsi sa Bongaka sa Hackensack University, Hackensack, New Jersey
Vaccine (6MHP) e nang le CDX-1127 kapa ntle le eona bakeng sa Phekolo ea Melanoma ea Stage IIB-IV
Teko ea mohato ona oa I / II e ithuta ka litla-morao le hore na ente ea (6MHP) e sebetsa joang kapa ntle le CDX-1127 bakeng sa kalafo ea melanoma ea IIB-IV. Divaksine, joalo ka 6MHP, li ka thusa 'mele ho aha karabelo e sebetsang ea boits'ireletso ba mmele ho bolaea lisele tsa hlahala. Immunotherapy e nang le lithibela-mafu tse monoclonal, joalo ka CDX-1127, e ka thusa boits'ireletso ba mmele ho hlasela mofets'e, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana. Teko ena e ntse e etsoa ho bona hore na 6MHP feela e na le litlamorao life hammoho le CDX-1127 liphetohong tsa sesole sa 'mele.
Sebaka: University of Virginia Cancer Center, Charlottesville, Virginia
Ipilimumab le Nivolumab le Immunoembolization ho Phekola Bakuli ba nang le Metastatic Uveal Melanoma Sebeteng
Karolo ena ea liteko tsa karolo ea II e ithuta ipilimumab le nivolumab ka ho itšireletsa mafung ho phekola bakuli ba nang le melanoma e nametsoeng ho ea sebeteng. Immunotherapy e nang le lithibela-mafu tse monoclonal, tse kang ipilimumab le nivolumab, e ka thusa sesole sa 'mele ho hlasela mofetše, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana. Ho itšireletsa mafung ho ka bolaea lisele tsa hlahala ka lebaka la tahlehelo ea phepelo ea mali le ho hlahisa boits'ireletso ba mmele khahlanong le lisele tsa hlahala. Ho fana ka ipilimumab le nivolumab ka ho itšireletsa mafung ho ka sebetsa hantle ho phekola bakuli ba nang le melanoma ea uveal.
Sebaka: Sepetlele sa Thomas Jefferson University, Philadelphia, Pennsylvania
Cyclophosphamide, Fludarabine, Lihlahala Tse Kenyetsang Li-Lymphocyte, le Aldesleukin ho Phekola Barupeluoa ka Metastatic Uveal Melanoma
Teko ea mohato ona oa II e ithuta hore na cyclophosphamide, fludarabine, hlahala e kenella ka har'a li-lymphocyte le aldesleukin e sebetsa joang ho phekoleng litho tsa sehlopha ka lefu la melanoma le nametseng libakeng tse ling 'meleng. Lithethefatsi tse sebelisitsoeng chemotherapy, joalo ka cyclophosphamide le fludarabine, li sebetsa ka litsela tse fapaneng ho emisa kholo ea lisele tsa hlahala, ekaba ka ho bolaea lisele, ka ho li emisa ho arohana, kapa ka ho li emisa ho hasana. Ho hlahala ho kenang ka lymphocyte e ka ba kalafo e sebetsang bakeng sa uveal melanoma. Aldesleukin e ka susumetsa lisele tse tšoeu tsa mali ho bolaea lisele tsa melanoma. Ho fana ka cyclophosphamide, fludarabine, hlahala e kenang ka li-lymphocyte le aldesleukin ho ka bolaea lisele tse ngata tsa hlahala.
Sebaka: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Autologous CD8 + SLC45A2-Specific T Lymphocyte e nang le Cyclophosphamide, Aldesleukin, le Ipilimumab ho phekola Barupeluoa ka Metastatic Uveal Melanoma
Karolo ena ea liteko tsa karolo ea Ib e hlahloba litla-morao le lethal dose e ntle ea li-lymphocyte tse ikhethileng tsa CD8 (+) SLC45A2 ha li fanoa hammoho le cyclophosphamide, aldesleukin, le ipilimumab, le ho bona hore na li sebetsa hantle hakae ho phekoleng bankakarolo ba nang le melanoma ea uveal e namileng dibakeng tse ding mmeleng. Ho etsa lisele tse khethehileng tsa CD8 + T, bafuputsi ba arola lisele tsa T tse bokelletsoeng maling a nkang karolo 'me ba li phekola hore li tsebe ho lebisa lisele tsa melanoma. Lisele tsa mali li khutlisetsoa ho morupeluoa. Sena se tsejoa e le "ho amohela phetisetso ea lisele tsa T" kapa "kalafo ea" cell "e amohelang". Lithethefatsi tse sebelisitsoeng chemotherapy, joalo ka cyclophosphamide, li ka sebetsa ka litsela tse fapaneng ho emisa kholo ea lisele tsa hlahala, ekaba ka ho bolaea lisele, ka ho li emisa ho arohana, kapa ka ho li emisa ho hasana. Phekolo ea likokoana-hloko, joalo ka aldesleukin, sebelisa lintho tse entsoeng ka lintho tse phelang tse ka matlafatsang sesole sa 'mele ka litsela tse fapaneng le ho emisa lisele tsa hlahala ho hola. Immunotherapy e nang le lithibela-mafu tse monoclonal, tse kang ipilimumab, e ka thusa boits'ireletso ba mmele ho hlasela mofets'e, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana. Ho fana ka li-lymphocyte tse ikhethileng tsa CD8 + SLC45A2 hammoho le cyclophosphamide, aldesleukin le ipilimumab ho ka sebetsa hantle ho phekoleng litho tsa sehlopha ka metastatic uveal melanoma.
Sebaka: Setsi sa Kankere sa MD Anderson, Houston, Texas
Nivolumab ea Intravenous le Intrathecal ho Phekola Bakuli ba nang le Lefu la Leptomeningeal
Karolo ena ea liteko tsa I / Ib e ithuta ka litla-morao le tekanyo e ntle ea intrathecal nivolumab, le hore na e sebetsa hantle hakae hammoho le nivolumab e kenang methapong ho phekola bakuli ba nang le lefu la leptomeningeal. Immunotherapy e nang le lithibela-mafu tse monoclonal, joalo ka nivolumab, e ka thusa boits'ireletso ba mmele ho hlasela mofets'e, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana.
Sebaka: Setsi sa Kankere sa MD Anderson, Houston, Texas
Nivolumab e nang le Ipilimumab kapa Relatlimab kapa pele ho Phekolo ea ho Phekola Bakuli ba nang le Melanoma ea Stage IIIB-IV e ka Tlosoang ke ho Buuoa
Teko ena ea mohato oa bobeli oa liteko tsa bobeli e bontša hore na nivolumab e na le kapa e se na ipilimumab kapa relatlimab pele ho ts'ebetso e sebetsa ho phekola bakuli ba melanoma ea IIIB-IV e ka tlosoang ka ho buuoa. Immunotherapy e nang le lithibela-mafu tse monoclonal, joalo ka nivolumab, ipilimumab, le relatlimab, e ka thusa sesole sa 'mele ho hlasela mofets'e, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana. Ho fana ka nivolumab feela kapa ho kopantsoe le ipilimumab kapa relatlimab pele ho ts'ebetso ho ka etsa hore hlahala e be nyane mme ho fokotsa boholo ba lisele tse tloaelehileng tse hlokang ho tlosoa.
Sebaka: Setsi sa Kankere sa MD Anderson, Houston, Texas
Ente ea 6MHP le Ipilimumab ho phekola bakuli ba nang le Melanoma ea IIA-IV
Teko ena ea karolo ea II / II e ithuta ka litla-morao tsa ente ea 6 ea melanoma helper peptide (6MHP) le ipilimumab le ho bona hore na ba sebetsa hantle hakae ho phekola bakuli ba melanoma ea IIA-IV. Meento e entsoeng ka li-peptide, joalo ka vaksine ea 6MHP, e ka thusa 'mele ho aha karabelo e sebetsang ea boits'ireletso ba mmele ho bolaea lisele tsa hlahala. Immunotherapy e nang le lithibela-mafu tse monoclonal, tse kang ipilimumab, e ka thusa boits'ireletso ba mmele ho hlasela mofets'e, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana. Ha ho tsejoe hore na ho fana ka ente ea 6MHP le ipilimumab ho sebetsa betere ho phekola bakuli ba melanoma.
Sebaka: University of Virginia Cancer Center, Charlottesville, Virginia
Dabrafenib Mesylate, Trametinib, le 6 Ente ea Melanoma Helper Peptide ho Phekola Bakuli ba nang le Melanoma ea IIIB-IV
Teko ena ea karolo ea II / II e ithuta ka litla-morao le hore na ente ea dabrafenib mesylate, trametinib, le 6 ea melanoma e thusang peptide e sebetsa joang ho phekola bakuli ba melanoma ea IIIB-IV. Dabrafenib mesylate le trametinib li ka emisa kholo ea lisele tsa hlahala ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea lisele. Meento, joalo ka vaksine e 6 ea melanoma helper peptide, e entsoeng ka li-peptide tse tsoang liprotheine tsa melanoma, e ka thusa 'mele ho aha boits'ireletso bo matla ba mmele ho bolaea lisele tsa hlahala tse hlahisang li-antigen tse ikhethang tsa melanoma. Ho fana ka ente ea dabrafenib, trametinib le 6 ea melanoma e thusang peptide e ka sebetsa hantle ho phekola bakuli ba melanoma.
Sebaka: University of Virginia Cancer Center, Charlottesville, Virginia
Sunitinib Malate kapa Valproic Acid ho Thibela Metastasis ho bakuli ba nang le kotsi e phahameng ea ho pepesa melanoma
Teko ena ea mohato oa bobeli oa boithuto e hlahloba hore na sunitinib malate kapa valproic acid e sebetsa joang ho thibela melanoma e kotsing ea kotsi (leihlo) ho hasana ho ea likarolong tse ling tsa 'mele. Sunitinib malate e ka emisa phetiso ea matšoao a kholo ho lisele tsa hlahala mme ea thibela lisele tsena ho hola. Valproic acid e ka fetola polelo ea liphatsa tsa lefutso tse ling ho melala ea melanoma le ho thibela kholo ea hlahala.
Sebaka: Sepetlele sa Thomas Jefferson University, Philadelphia, Pennsylvania
Ho ruruha ho kenang ka har'a li-lymphocyte le High-Dose Aldesleukin kapa ka ntle ho Autologous Dendritic Cell ho Phekola Bakuli ba nang le Metastatic Melanoma.
Teko ena ea mohato oa bobeli oa boithuto e ithuta hore na hlahala ea kalafo e kenella ka har'a lymphocyte le aldesleukin e nang le lethal dose e nang le lisele tsa dendritic tsa autologous li sebetsa joang ho phekola bakuli ba melanoma e nametseng libakeng tse ling tsa 'mele. Liente tse entsoeng ka lisele tsa hlahala tsa motho le lisele tse khethehileng tsa mali (lisele tsa dendritic) li ka thusa 'mele ho aha karabelo e sebetsang ea boits'ireletso ba mmele ho bolaea lisele tsa hlahala. Aldesleukin e ka susumetsa lisele tse tšoeu tsa mali ho bolaea lisele tsa hlahala. Ha ho e-so tsejoe hore na hlahala ea kalafo e kenang ka har'a lymphocyte le aldesleukin e nang le lethal dose e sebetsa hantle ha e fanoa hammoho kapa ntle le lisele tsa dendritic ho fokotseha kapa ho liehisa kholo ea melanoma. Melemo ea kliniki ea ho amohela li-lymphocyte tse kenang ka hlahala (TIL) hammoho le B-Raf proto-oncogene, serine / threonine kinase (BRAF) inhibitor e tla ithutoa, ho bakuli ba nang le lefu le tsoelang pele (PD) ka ho sebelisa BRAF inhibitor pele ho kalafo ea TIL. Lefu la Leptomeningeal (LMD) ka bomalimabe ke nts'etsopele e tloaelehileng ho bakuli ba melanoma, ba nang le ts'oaetso e mpe haholo, e fetolelang ho phela libeke tse ngata feela. Ka mokhoa o mocha oa ho kopanya li-intrathecal TILs le intrathecal interleukin (IL) -2, bafuputsi ba na le tšepo ea ho baka botsitso ba lefu la nako e telele kapa ts'oarelo ea LMD.
Sebaka: Setsi sa Kankere sa MD Anderson, Houston, Texas
Vorinostat ea Phekolo ea Melanoma ea Kotsi ea 2 e Kotsing e Kotsi
Mokhahlelo ona oa pele oa liteko tsa liteko tsa hore na vorinostat e sebetsa joang ho phekola bakuli ba nang le kotsi ea melanoma e kotsi. Bafuputsi ba fumana hore lisele tsa uveal melanomas hangata li arotsoe ka mefuta e 'meli: sehlopha sa 1 le sehlopha sa 2. Lisele tsa sehlopha sa 2 li na le monyetla o moholo oa ho fetela lithong tse ling tsa' mele, ha lisele tsa sehlopha sa 1 hangata li lula ka har'a 'mele. leihlo. Vorinostat e ka khona ho fetola lisele tsa sehlopha sa 2 hore e be lisele tsa mofuta oa 1 tse seng mabifi ka ho "bulela" liphatsa tsa lefutso tse ka seleng tse hatellang lihlahala.
Sebaka: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Ulixertinib ho Phekola bakuli ba nang le Stage IV Uveal Melanoma
Teko ea mohato ona oa II e ithuta ka litla-morao tsa ulixertinib le hore na e sebetsa hantle hakae ho phekoleng bakuli ba nang le melanoma ea IV. Ulixertinib e ka emisa kholo ea lisele tsa hlahala ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea lisele.
Sebaka: Bona Clinical Trials.gov
Vorinostat ea ho Phekola Bakuli ba nang le Metastatic Melanoma ea Leihlo
Teko ea mohato ona oa II e ithuta hore na vorinostat e sebetsa hantle joang ho phekoleng bakuli ba melanoma ea leihlo e nametseng likarolong tse ling tsa 'mele. Vorinostat e ka emisa kholo ea lisele tsa hlahala ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea lisele.
Sebaka: Bona Clinical Trials.gov
